BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced that its management will present at the 16th Annual LD Micro Invitational in Los Angeles, California. The presentation is scheduled for Monday, May 18, 2026, at 1:30 PM ET. Interested parties can access live and archived webcasts on the investors section of the company's website at ir.biostemtechnologies.com.
This event provides a platform for BioStem to discuss its proprietary processing technologies and product portfolio. The company's technologies include BioRetain®, CryoTek®, and SteriTek®, which are designed to preserve the natural properties of perinatal tissues for clinical use. BioStem's allografts are utilized across various medical specialties, and the company has a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint.
BioStem's quality management system has been reviewed and accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP). The company's product lines include Neox®, Clarix®, VENDAJE®, and American Amnion™.
The LD Micro Invitational is a key conference for the micro-cap investment community, and BioStem's participation underscores its commitment to advancing innovation in regenerative medicine. The presentation may highlight recent developments and future directions, offering insights for investors and industry observers. As a publicly traded company, BioStem's performance and strategic initiatives are of interest to shareholders and potential investors.
BioStem Technologies is focused on developing, manufacturing, and commercializing advanced allograft solutions. Its technologies aim to optimize tissue preservation, supporting clinicians in wound care and other applications. The company's national presence and ongoing research efforts position it within the broader regenerative medicine market, which has been growing due to increasing demand for advanced therapeutic options.
The implications of BioStem's presentation at this conference include potential increased visibility among investors and partners, which could influence the company's stock performance and ability to secure funding for research and expansion. For the industry, BioStem's innovations in tissue processing may contribute to improved patient outcomes and set standards for quality in allograft manufacturing. The event also allows stakeholders to assess the company's progress and strategic direction.
For more information about BioStem Technologies, visit the company's website at www.biostemtechnologies.com and follow the company on X at @BSEM_Tech. The latest news and updates relating to $BSEM are available in the company's newsroom at https://tinyurl.com/bsemnewsroom.
